Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

and clinics across the country," a spokesperson for Pfizer told Newsweek in an email. More From Newsweek Vault: Compare the ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

Pfizer and Moderna’s messenger RNA-based shots have ... from the three vaccine makers from June through December pales in ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Bourla and Afeyan said they began talking about this new approach in the depths of the pandemic, when they were “partners-slash-competitors,” as Bourla puts it, in the effort to create a vaccine.

It will compare the shot against a ... to a current vaccine due to start shortly. Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald ...

But what Sam Bankman-Fried did pales in comparison, in my opinion, to the fraud that was perpetrated by Moderna and Pfizer. TRAVIS: Not only did the shots fail, via fraud you were encouraged and ...

Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...